AU-105

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAU-105
Drug Alias NameAU-105
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > γ-retroviral vector
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT lymphocyte replacements
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAttralus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAttralus Inc
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A